araag2/HINT huggingface dataset:
Clinical trial NCT00582556 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: zometa, zometa, zometa
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have a histologic diagnosis of adenocarcinoma of the prostate.

          -  For patients without clinical metastasis treated by surgery, serum PSA values must be
             > 0.2 ng/ml by two measurements at least two weeks apart. In patients treated with
             ablative radiation therapy without clinical metastasis, three consecutive increases in
             serum PSA must be documented, with at least a one-month interval between values with
             the final PSA > 2ng/m as evidence of biochemical PSA failure. P

          -  Patients who have not had prior primary therapy such as radiation or surgery, are
             required to have a detectable PSA of at least 0.2 ng/ml.

          -  Patients with evidence of metastatic disease are eligible irrespective of serum PSA
             level.

          -  Prior history of a second malignancy is allowed if treated with curative intent and
             patient has been free of disease greater than five years

          -  ECOG performance status of < 2.

        Exclusion Criteria:

          -  Prior treatment with a GnRH analogue or anti-androgen.

          -  Evidence of immunosuppression or have been treated with immunosuppressive therapy,
             such as chemotherapy, chronic treatment dose corticosteroids, or radiation therapy to
             bones, within 6 months of study enrollment

          -  Current or treatment within 4 weeks with estrogen or estrogenic agents (including
             herbal compound PC-SPES)

          -  Current or treatment within 4 weeks with herbal compounds for prostate cancer such as
             PC-SPES or saw palmetto

          -  Current or treatment within 4 weeks with megestrol

          -  Current or prior treatment with a bisphosphonate, calcitonin, or other bone
             resorptive/anabolic agents

          -  Current use of oral corticosteroids or any such use within the past 6 months

          -  Current use of potentially bone-toxic anticonvulsants (phenytoin, or carbamazepine)

          -  History of orchiectomy

          -  Hypocalcemia
Clinical trial NCT01208090 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: act-128800, placebo
SMILES: CCC\N=C1/S\C(=C/C2=CC=C(OC[C@H](O)CO)C(Cl)=C2)C(=O)N1C1=CC=CC=C1C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult males and females aged 18 to 60 years (inclusive) with moderate to severe
             chronic plaque psoriasis who require systemic treatment.

        Exclusion Criteria:

          -  Patients with other forms of psoriasis and patients who are currently treated for
             autoimmune disorders other than psoriasis.

          -  Systemic or topical treatments for psoriasis other than emollients. Ongoing bacterial,
             viral or fungal infections.

        History or presence of malignancy.

          -  Additional inclusion and exclusion criteria apply with respect to medical conditions
             and concomitant treatments which could affect patients' risk from participating in the
             study.
Clinical trial NCT01155362 (phase 2, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: vehice control
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Males and females ages 18-75 years

          2. Understand and voluntarily sign an informed consent

          3. Able to adhere to the study visit schedule and other protocol requirements

          4. Minimum weight of 50 kg

          5. A female of childbearing potential (FCBP)† must have a negative urine pregnancy test
             at screening (Visit 1) and immediately prior to all doses of IP. In addition, sexually
             active FCBP must agree to use two of the adequate forms of contraception methods for
             the duration of the study and the follow-up period. A FCBP must agree to have
             pregnancy tests at least every 4 weeks during the study. Males (including those who
             have had a vasectomy) must agree to use barrier contraception (latex condoms) when
             engaging in reproductive sexual activity with FCBP for the duration of the study and
             the follow-up period.

          6. Subject must have inflammatory CD 6 months prior to treatment and have confirmation of
             ongoing disease activity by colonoscopy or (other method) at screening

          7. Subject must have a CDAI score > 220 and < 450 as assessed between Visit 1 and Visit 2

          8. The Subject must have failed, i.e., had an inadequate response or lost response
             (recurrence of symptoms) to an agent, or documented intolerance to an agent at any
             time

        Exclusion Criteria:

          1. Any significant medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from participating in the study

          2. Any condition including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study

        A female of childbearing potential is a sexually mature woman who:

          1. has not undergone a hysterectomy or bilateral oophorectomy

          2. has not been naturally postmenopausal for at least 24 consecutive months (i.e., has
             had menses at any time in the preceding 24 consecutive months).
Clinical trial NCT00708552 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: sb-742457, donepezil, placebo
SMILES: O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Subjects and their caregivers must provide informed consent prior to study entry.

          -  Subjects must have a clinical diagnosis of probable mild-to-moderate Alzheimer's
             disease with a documented 6-month history of AD symptoms

          -  Subjects must have a regular caregiver who is willing to attend visits, oversee the
             subject's compliance with the study and report on the subject's status.

          -  Female subjects of child-bearing potential must agree to pregnancy testing and
             approved form of birth control.

        Exclusion criteria:

          -  Diagnosis of possible, probable or definite vascular dementia.

          -  History/evidence of any other CNS disorder that could be interpreted as a cause of
             dementia

          -  History of known or suspected seizures, loss of consciousness or significant head
             trauma

          -  Subjects with ECG, blood pressure and laboratory values outside of protocol criteria
             are excluded.

          -  Subjects with known photosensitivity

          -  Subjects with a history of previous exposure to SB-742457, taking agents for which
             there is a theoretical risk of interaction with SB-742457, or taking medication for
             Alzheimer's disease or centrally acting agents which might impact study outcomes may
             not participate.
Clinical trial NCT01032291 (phase 2, status: terminated)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cetuximab, lenalidomide
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Reason stopped: 
    a business decision not to continue with phase 2b based on non-safety observations during proof
    of concept phase.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Metastatic colorectal adenocarcinoma.

          2. Confirmed K-RAS mutant tumor

          3. Disease progression on oxaliplatin- AND irinotecan-containing regimens, with at least
             one of these regimens containing bevacizumab.

          4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.

        Exclusion Criteria:

          1. Use of chemotherapy, hormonal therapy, immunotherapy or any other cancer or
             experimental treatment ≤ 28 days prior to the first day of the first cycle.

          2. Radiotherapy for up to ≥ 30% of the bone marrow.

          3. Surgery ≤ 28 days before day 1 of the first cycle (minimally invasive interventions
             for diagnostic purposes or disease staging are permitted).

          4. Previous treatment with cetuximab, panitumumab, pomalidomide (CC-4047), lenalidomide
             or thalidomide.

          5. Untreated, symptomatic brain metastases (brain imaging not required).

          6. Venous thromboembolism ≤ 6 months before day1 of the first cycle.

          7. Current congestive heart failure (classes II to IV of the New York Heart Association).

          8. Myocardial infarction ≤ 12 months before day1 of the first cycle.

          9. Uncontrolled hypertension.
Clinical trial NCT00003640 (phase 2, status: terminated)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine sulfate
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Transitional cell carcinoma of the bladder with biopsy proven
        muscle invasion suitable for resection leaving no residual visible or palpable tumor mass
        Unifocal No greater than 5 cm Stages II and III (T2-T3a, N0-NX, M0) No prior treatment for
        bladder cancer other than endoscopic resection, intravesical chemotherapy, or intravesical
        immunotherapy

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: WHO 0-1 Life expectancy:
        Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 120,000/mm3
        Hepatic: Bilirubin normal SGOT/SGPT normal Renal: GFR at least 50 mL/min Cardiovascular:
        Normal cardiac function (i.e., no New York Heart Association class II-IV) Other: Normal
        auditory function No second primary malignant tumor except basal cell carcinoma of the skin
        Fit for cisplatin containing combination chemotherapy, radical radiotherapy, or cystectomy
        No active infections Not pregnant or nursing No concurrent illness that significantly
        affects clinical assessments

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See
        Disease Characteristics No prior systemic chemotherapy Endocrine therapy: Not specified
        Radiotherapy: No prior radiotherapy to the bladder Surgery: See Disease Characteristics No
        prior partial cystectomy Prior transurethral resection of the bladder allowed
Clinical trial NCT00120653 (phase 2, status: withdrawn)
Conditions: myelodysplastic syndromes
ICD codes: D46.9, D46.C, D46.Z
Drugs: metoclopramide
SMILES: CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
Eligibility criteria:

        -  INCLUSION CRITERIA:

               1. MDS patients in IPSS risk group low or intermediate-1

                  OR

                  MDS patients in IPSS risk group intermediate-2 if greater than 60 years of age
                  and not eligible for high intensity therapies, including intensive combination
                  chemotherapy or hematopoietic cell transplant.

               2. Off all other treatments for MDS, except red blood cell transfusion support for
                  at least 4 weeks.

               3. Anemia as defined by hemoglobin less than 11g/dL.

               4. Absolute reticulocyte count less than 60,000/microliter based on two baseline lab
                  tests.

               5. Absolute neutrophil count greater than 200/microliter.

               6. Platelet count greater than 10,000/microliter.

               7. Ages 18 to 72.

               8. ECOG performance status less than or equal to 2.

               9. Ability to understand the investigational nature of the protocol and provide
                  informed consent.

        EXCLUSION CRITERIA:

          1. MDS patients in high IPSS risk group.

          2. Patients with secondary MDS.

          3. Previous history of dystonic reaction and/or anaphylactic reaction to metoclopramide.

          4. History of GI obstruction/perforation, pheochromocytoma, seizure disorders, creatinine
             clearance less than or equal to 50mL/min (estimated creatinine clearance = [weight
             (Kg) x (140-age) x (0.85 if female)]/[72 x (stable creatinine)], Parkinson's disease,
             breast cancer, clinically active depression, or hypertension due to pheochromocytoma

          5. Current pregnancy (positive serum Beta-HCG if menstruating female), or unwilling to
             use a medically acceptable contraceptive or refrain from pregnancy if of childbearing
             potential

          6. Concomitant drug therapy with high risks of extrapyramidal side effects (namely
             antipsychotic drugs including haloperidol, trifluoperazine, fluphenazine, thiothixene,
             perphenazine and pimozide).

          7. Metoclopramide therapy 4 months prior to study enrollment.

          8. Hyperprolactinemia prior to study implementation (prolactin greater than 200 ng/ml).
Clinical trial NCT00674973 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: erlotinib, placebo
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  histologically or cytologically documented locally advanced-unresectable or metastatic
             pancreatic cancer;

          -  measurable disease according to RECIST;

          -  failure of at least one prior chemotherapy regimen, or who are deemed unsuitable for
             chemotherapy;

          -  ECOG performance status of 0-2.

        Exclusion Criteria:

          -  local or locally advanced-resectable pancreatic cancer;

          -  any other malignancies within last 5 years, except for adequately treated cancer in
             situ of the cervix, or basal or squamous cell skin cancer;

          -  major surgery within 2 weeks prior to randomization.
Clinical trial NCT00602199 (phase 2, status: completed)
Conditions: melanoma (skin)
ICD codes: C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, D03.52
Drugs: abt-510
SMILES: CCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN(C)C(C)=O)C(C)C)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignant melanoma

               -  Stage IV disease

               -  No known potentially curative standard therapy that exists or is proven capable
                  of extending life expectancy

          -  Measurable disease

          -  No history of or current CNS metastases

               -  MRI of the brain to confirm absence of CNS metastases within the past 28 days is
                  required

          -  No known, presently active carcinomatous meningitis

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 6 months

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)

          -  AST ≤ 3 times ULN

          -  Creatinine ≤ 2.5 times ULN

          -  Hemoglobin ≥ 9.0 g/dL

          -  Prothrombin time normal

          -  Willing to return to Mayo Clinic Rochester, Jacksonville or Scottsdale for follow-up

          -  Must be able to self-administer or has a caregiver who can reliably administer
             subcutaneous injections

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No uncontrolled or current infection

          -  No New York Heart Association class III-IV heart disease

          -  No recent history of (i.e., ≤ 12 weeks from study day 1) or current cancer-related
             bleeding event (e.g., hemoptysis)

          -  No recent history of (within the past 4 weeks) or current noncancer-related clinically
             significant bleeding event

          -  No uncontrolled hypertension

          -  No history of stroke or other CNS bleeding events (e.g., aneurysms)

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since prior chemotherapy and recovered (6 weeks for mitomycin C or
             nitrosoureas)

          -  At least 4 weeks since prior immunotherapy, biologic therapy, radiotherapy, or surgery

          -  No concurrent anticoagulation therapy or antiplatelet therapy

          -  No other concurrent antineoplastic agents (e.g., cytotoxic chemotherapy,
             immunotherapy, radiotherapy, or investigational therapy) except local radiotherapy for
             supportive reasons involving a small radiation field
Clinical trial NCT00398047 (phase 2, status: terminated)
Conditions: leukemia, myelodysplastic syndromes
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D46.9, D46.C, D46.Z
Drugs: azacitadine and hematopoietic growth factors
SMILES: NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of myelodysplastic syndromes (MDS)

               -  Bone marrow aspirate and biopsy with karyotyping performed within the past 8
                  weeks

          -  Patients with chronic myelomonocytic leukemia (CMML), refractory anemia (RA), or
             refractory anemia with ringed sideroblasts (RARS) according to FAB classification OR
             RA, RARS, refractory anemia with multilineage dysplasia, or RARS with multilineage
             dysplasia according to WHO classification must meet ≥ 1 of the following criteria:

               -  Symptomatic anemia requiring RBC transfusion for ≥ 3 months before study entry

               -  Thrombocytopenia with ≥ 2 platelet counts < 50,000/mm³ OR a significant
                  hemorrhage requiring platelet transfusion

               -  Neutropenia with an absolute neutrophil count < 1,000/mm³ and an infection
                  requiring IV antibiotics

          -  No refractory anemia with excess blasts in transformation

          -  No history of leukemia

          -  No known primary or metastatic hepatic tumor

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy > 2 months

          -  AST and ALT ≤ 2 times upper limit of normal

          -  Creatinine < 2.0 mg/dL

          -  Serum vitamin B12 normal

          -  Serum and/or red cell folate levels normal

          -  Ferritin ≥ 50 ng/mL

          -  Copper > 40 µg/dL

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Negative pregnancy test

        PRIOR CONCURRENT THERAPY:

          -  No prior azacitidine or decitabine

          -  No prior therapy for MDS

               -  Supportive therapy within the past 28 days allowed

          -  No other concurrent treatment for MDS (i.e., thalidomide, arsenic trioxide,
             cyclosporine, or melphalan)

          -  No other concurrent hematopoietic growth factors, including epoetin alfa, filgrastim
             (G-CSF), sargramostim (GM-CSF), or interleukin-11 (oprelvekin)
Clinical trial NCT01489332 (phase 2, status: unknown status)
Conditions: rectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: intensified preoperative chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients with histologically proven adenocarcinoma of the rectum
             (tumour located below the peritoneum),

          -  T3/4 or any node positive disease (clinical stage according the TNM classification
             system)

          -  No evidence of metastatic disease.

          -  The disease must be considered either resectable at the time of entry or thought to
             become resectable after preoperative chemoradiation.

          -  Age 18 years and more

          -  WHO Performance Status 0-2

          -  No prior radiotherapy, chemotherapy or any targeting therapy for rectal cancer

          -  Adequate hematological, hepatic and renal function Ability to swallow tablets

          -  Signed informed consent

          -  Patients must be willing and able to comply with the protocol for duration of the
             study

        Exclusion Criteria:

          -  Malignancy of the rectum other than adenocarcinoma

          -  Any unrested synchronous colon cancer

          -  Other co-existing malignancy or malignancy within the past 5 years, with the exception
             of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the
             skin

          -  Significant heart disease (uncontrolled hypertension despite of medication (> 150/100
             mmHg), NYHA class III or IV heart disease,unstable angina or myocardial infarction
             within the past 1 year prior the study entry, history of significant ventricular
             arrhythmia requiring treatment)

          -  Pregnant or lactating patient

          -  Females with a positive or no pregnancy test unless childbearing potential can be
             otherwise excluded (amenorrheic for at least 2 years,hysterectomy or oophorectomy)